This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q78.0 (osteogenesis imperfecta) | Special Copayment Reduction: V183 (rare disease) |
| B. Synonyms | Osteogenesis imperfecta | Fragilitas ossium | Osteopsathyrosis |
| C. Adult onset | Likelihood of first presentation in adulthood: intermediate — type I (mild) is not uncommonly first diagnosed in adulthood with fractures or hearing loss, whereas types II and III are almost all diagnosed in the perinatal period or childhood; some type IV cases are first discovered in adolescence or adulthood. In mild phenotypes, the diagnosis is sometimes made late, overlapping with postmenopausal decline in bone density. |
| 1. History | Traces found in ancient Egyptian mummies → clinical descriptions in 17th-century Europe → 1788 first systematic report by Ekman → 1849 Lobstein named it 'osteogenesis imperfecta' → 1979 establishment of the Sillence classification → 1980s identification of COL1A1/COL1A2 mutations → 2000s bisphosphonates become standard therapy. |
| 2. Causes | COL1A1 or COL1A2 gene mutations (type I collagen defects) in about 90% of all cases. The remaining 10% are mutations in genes related to collagen processing, modification and folding, such as IFITM5, SERPINF1, CRTAP, LEPRE1 and PPIB. High frequency of de novo mutations. |
| 3. Genetics | Mostly autosomal dominant (AD). The Sillence classification of types I~IV is classic; types V~XIII are mainly autosomal recessive (AR). COL1A1 (17q21.33), COL1A2 (7q21.3). Severity determined by mutation type. De novo mutations common in severe forms. |
| 4. General epidemiology | About 1 in 10,000~20,000 births. An estimated 500,000 people worldwide. Estimated 500~1,000 patients in Korea. Independent of sex and ethnicity. Severe type II is lethal in the perinatal period; type I is the most common (about 50% of the total). |
| 5. Pathophysiology | Defects in the triple-helix structure of type I collagen reduce bone matrix synthesis or cause structural abnormalities. Quantitative collagen reduction (type I) gives a mild phenotype; structural abnormalities (glycine substitutions, etc.) give moderate to severe phenotypes. Reduced osteoblast function and early death, reduced bone density, thinning of cortical bone and abnormal trabecular bone structure lead to fragile bone. |
| 6. Symptoms | Recurrent fractures from minor trauma, bone deformities (scoliosis, bowing of long bones), short stature, blue sclerae (characteristic of type I), abnormal tooth development (dentinogenesis imperfecta), hearing loss, joint hypermobility, muscle weakness. Type II: multiple perinatal fractures, fatal respiratory failure. |
| 7. Signs | X-ray: reduced bone density, thin cortical bone, vertebral compression fractures (codfish vertebrae), long bone deformities. DXA: markedly reduced Z-score. Blue sclerae (mild to moderate forms). Triangular facies. Wormian bones in the skull. 'Codroid' chest (type II). Bowing and shortening of bones. |
| 8. Screening | Prenatal ultrasound when there is a family history (16~20 weeks of gestation, shortening and bowing of long bones). Prenatal genetic testing (CVS/amniocentesis). Neonatal X-rays. DXA + serum collagen markers in children and adults with recurrent fractures. Confirmation by gene panel testing. |
| 9. Diagnosis | Clinical and imaging diagnosis: fracture pattern on X-ray, DXA bone density, clinical features. Biochemistry: serum type I collagen metabolism markers. Confirmation: gene panel NGS including COL1A1/COL1A2. Analysis of collagen synthesis in skin fibroblasts (adjunct). Differentiation from child abuse is important. |
| 10. Treatment | Bisphosphonates (intravenous pamidronate, zoledronate) are the main drug treatment. Denosumab and anti-sclerostin antibodies (clinical trials). Immobilization or surgery for fractures, intramedullary rodding (children). Surgery for scoliosis and basilar invagination. Physical therapy and rehabilitation. Assistive devices. Hearing aids. |
| 11. Prognosis | Type I: life expectancy close to normal. Type II: mostly perinatal death. Type III: severe functional impairment, early death possible. Type IV: moderate disability, reduced quality of life. Bisphosphonate treatment reduces fracture frequency. Gene therapy research under way. |
| 12. Prevention | Genetic counseling and prenatal diagnosis (CVS). Education on safe positioning and fall prevention. Adequate calcium and vitamin D intake. Low-impact exercise. Creating a fracture-preventing environment. Regular DXA follow-up. Fracture prevention through early initiation of bisphosphonate treatment. |
| 13. References | Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016 … and 9 other papers |
The history of osteogenesis imperfecta goes back thousands of years. Bone deformities consistent with this disease have been found in ancient Egyptian mummies (around 1000 BC), and similar pathological findings have been reported in the remains of Scandinavian Vikings. In Europe, individual cases characterized by recurrent fractures and bone deformities began to be reported from the 17th century. The Swedish physician Olof Jacob Ekman systematically described a family with recurrent fractures over several generations in his 1788 doctoral dissertation, which is regarded as the first scientific report on osteogenesis imperfecta. Ekman intuitively grasped the hereditary tendency of the disease, but the laws of inheritance were not known at the time.
In the 19th century, attempts were made in European medicine to name and classify this disease. In 1849, Johann Friedrich Georg Christian Martin Lobstein of Germany first used the name 'osteogenesis imperfecta' while clinically describing 'bone fragility.' Around the same time, Braitenlocher of Germany and Eckle of England also reported similar cases. By the end of the 19th century, the clinical difference between the perinatally lethal form (today's type II) and nonlethal forms began to be recognized.
In the first half of the 20th century, pathological and radiological research advanced. In 1906, von Recklinghausen of Germany described cortical thinning and abnormal trabecular structure on bone tissue examination. In the 1940s~50s, intramedullary rod insertion was attempted and began to be applied to correct long bone deformities, and in 1959 Sofield and Millar published the technique of multisegmental osteotomy followed by rod fixation, contributing to improved walking function in severe patients. In 1959, Fraser of England also proposed the name 'Fragilitas ossium.'
The turning point in modern understanding came in 1979, when David Sillence and colleagues in Australia systematically classified osteogenesis imperfecta into types I~IV based on clinical features, mode of inheritance and imaging findings. This Sillence classification was used as the clinical standard for decades. In the molecular biology era, from the mid-1980s, COL1A1 and COL1A2 gene mutations were identified as the main cause of osteogenesis imperfecta, and Paul Byers, Peter Prockop and others led research in this field. Since the 1990s, advances in molecular genetic technology have identified hundreds of mutations.
In treatment, as the use of bisphosphonates—particularly intravenous pamidronate—in pediatric osteogenesis imperfecta was systematized in the early 2000s, reduced fracture frequency and improved bone density were reported. In 2006, the efficacy of pamidronate was confirmed in a large study in Canada (Rauch et al.). From 2008, once- or twice-yearly zoledronate administration was also applied in adults and children. In the 2010s, new types (V~XIII) caused by recessive mutations in genes related to collagen processing, such as SERPINF1, CRTAP, LEPRE1, PPIB and FKBP10, were described one after another. In the 2020s, clinical trials of drugs with new mechanisms, such as an anti-sclerostin antibody (romosozumab), an anti-RANKL antibody (denosumab) and a TGF-β neutralizing antibody (fresolimumab), are under way, and stem cell therapy and gene editing therapy are also at the research stage. In Korea, bisphosphonates are covered by National Health Insurance along with rare disease Special Copayment Reduction (V183) registration.
Osteogenesis imperfecta is caused by quantitative reduction or qualitative abnormality of type I collagen, the main structural protein of bone. Pathogenic variants in the COL1A1 (17q21.33) or COL1A2 (7q21.3) gene are found in about 90% of all patients. Type I collagen is a triple-helix structure (heterotrimer, [α1]₂α2) composed of two α1 chains (product of COL1A1) and one α2 chain (product of COL1A2), and is the main structural protein of bone, skin, tendons and ligaments.
COL1A1 or COL1A2 gene mutations act through two main mechanisms. First, reduced protein synthesis (quantitative defect): when one allele loses function (premature termination due to nonsense variants, frameshifts, etc.), production of normal chains is halved and the total amount of type I collagen in the bone matrix decreases. In this case, the collagen produced is structurally normal, so it is associated with a mild phenotype (type I). Second, structural abnormality (qualitative/structural defect): when a missense variant substitutes another amino acid for a glycine residue essential for triple-helix formation, the whole structure becomes unstable as the abnormal chain forms a triple helix together with normal chains. In this so-called 'dominant negative' mechanism, one abnormal chain combines with two normal chains and makes the entire triple helix abnormal. Severity is determined by the position of the glycine substitution (more severe the closer to the C-terminus) and the type of substituting amino acid, and this is associated with moderate (types III, IV) and severe phenotypes.
In the remaining about 10% of patients, mutations are found in genes involved in collagen post-translational modification, folding, secretion and processing. The main genes include IFITM5 (type V, autosomal dominant, formation of bisphosphonate attachment plates), SERPINF1 (type VI, autosomal recessive, deficiency of pigment epithelium-derived factor PEDF), CRTAP (type VII), LEPRE1/P3H1 (type VIII), PPIB (type IX), SERPINH1 (type X), FKBP10 (type XI), SP7/OSX (type XII) and BMP1 (type XIII). These types are mostly autosomal recessive and cause collagen structural abnormalities through deficient hydroxylation, disulfide bonding and molecular chaperone function of the collagen triple helix.
A clinically important point is the high frequency of de novo mutations. Particularly in the severe forms (types II, III), new mutations often arise in the patient even though the parents' genetic tests show no pathogenic variant. This means that de novo mutations arise at the germline stage of a parent, or that there is a risk of transmission to subsequent children through germline mosaicism. Therefore, genetic counseling on recurrence risk is needed even when a mutation appears to be de novo.
The mode of inheritance of osteogenesis imperfecta varies by type. The most common types I~IV (Sillence classification) mainly follow autosomal dominant (AD) inheritance. Because inheritance is AD, it is transmitted from an affected parent to a child with a 50% probability. However, in the severe forms (types II, III), the proportion of de novo mutations is high, so the absence of a family history is common.
The newly described types from type V onward are mostly inherited in an autosomal recessive (AR) manner: both parents are carriers, and the disease manifests in children with a 25% probability. AR types are relatively rare and more frequent in consanguineous families and in populations with founder effects.
The COL1A1 gene is located on the long arm of chromosome 17 (17q21.33) and consists of 51 exons. The COL1A2 gene is located on the long arm of chromosome 7 (7q21.3) and contains 52 exons. In both genes, exons encoding the repeating Gly-X-Y sequence essential for collagen triple-helix formation make up the majority. Glycine (Gly), the smallest amino acid, sits on the central axis of the triple helix, and substitution with another amino acid interferes with triple-helix formation through steric hindrance.
The genotype-phenotype correlation is complex but shows certain tendencies. Simple loss-of-function (haploinsufficiency) variants of COL1A1 mainly cause mild disease (type I). In contrast, glycine substitution missense variants of COL1A1 or COL1A2 are associated with moderate to severe disease (types II~IV). Glycine substitutions closer to the C-terminus (especially after COL1A1 Gly988) tend to be more severe than N-terminal substitutions. However, phenotypic diversity exists even with the same variant, suggesting the influence of genetic background (modifier genes). Dentinogenesis imperfecta (DI) occurs with COL1A1/COL1A2 variants and is distinguished from variants in dental genes such as DSPP.
Recessive variants in CRTAP, LEPRE1 (P3H1), PPIB and others are involved in prolyl hydroxylation, a step before collagen triple-helix formation; these proteins form a complex in the ER that catalyzes Lys87 hydroxylation of the collagen α2(I) chain. Deficiency of this complex causes overmodification of collagen and delayed triple-helix formation, resulting in severe bone abnormalities. PEDF (pigment epithelium-derived factor), the product of the SERPINF1 gene, affects osteoblast differentiation and function, and its deficiency causes type VI, in which unmineralized osteoid accumulates.
Molecular diagnosis is performed with a rare skeletal disease panel (NGS) including dual COL1A1/COL1A2 gene analysis or with whole exome sequencing (WES). When a variant is identified, parental testing distinguishes de novo from inherited variants, and this is used for recurrence risk estimation and genetic counseling.
Osteogenesis imperfecta is a rare genetic skeletal disease occurring worldwide at a frequency of about 1 in 10,000~20,000 births, regardless of ethnicity, region or sex. There are estimated to be about 500,000 patients worldwide, and because many mild cases go undiagnosed in regions with poor diagnostic access, the actual prevalence is likely higher. Of all types, type I (mild) is the most common, accounting for about 50% of the total, with type III (severe progressive) and type IV (moderate) each accounting for about 20~25% and type II (perinatally lethal) for about 5~10%.
Epidemiology in Korea: accurate prevalence statistics in Korea are limited, but the estimated number of patients based on Health Insurance Review & Assessment Service (HIRA) and rare disease registry data is known to be about 500~1,000. The number of patients registered for Special Copayment Reduction (V183) is gradually increasing each year, and a multidisciplinary treatment system in which pediatrics, orthopedics, rehabilitation medicine and genetics collaborate has been established, centered on large centers such as Asan Medical Center and Seoul National University Hospital.
The prevalence of osteogenesis imperfecta does not differ greatly by race or ethnicity, but certain founder mutations have been reported at high frequency in some ethnic groups. For example, a specific COL1A1 variant has been reported at high frequency in Black South Africans, and there are reports of a high frequency of a recessive CRTAP variant in the Amish community.
Because the mode of inheritance is not X-linked, it occurs equally in men and women. However, in adult women, bone density falls further as it overlaps with the postmenopausal decline in estrogen, and fracture frequency tends to increase, so some cases are first diagnosed in adult women (mild type I). In type II, most patients die within a few weeks after birth from multiple intrauterine fractures and perinatal respiratory failure, so it may be undercounted in prevalence data.
Patient support organizations for osteogenesis imperfecta (e.g., OI Foundation, Brittle Bone Society) are active worldwide, and the International Federation of Osteogenesis Imperfecta Societies (IFOIS) leads patient education and research support. In Korea, support and information sharing are provided through the Korean Alliance of Rare and Intractable Diseases.
The core pathophysiology of osteogenesis imperfecta is skeletal fragility due to quantitative and qualitative abnormalities of type I collagen. Normally, the type I collagen triple helix is formed in the endoplasmic reticulum (ER) as two α1 chains and one α2 chain wind from the C-terminus toward the N-terminus, and during this process hydroxylation of proline (Pro) and lysine (Lys) residues, cross-linking with matrix proteins in the skeleton and formation of the extracellular matrix proceed in sequence.
With loss-of-function (haploinsufficiency) variants of COL1A1/COL1A2, production of the normal collagen triple helix is halved (quantitative defect), so collagen fiber density in the bone matrix is reduced. In this case the collagen structure itself is normal, so although the mechanical properties of bone are lower than normal, the phenotype is milder than with structural abnormalities. In contrast, with glycine substitution missense variants, the abnormal chain attempts to form a triple helix together with normal chains, but steric hindrance at the glycine position delays triple-helix formation, and overhydroxylation and abnormal cross-linking of collagen molecules occur. When this defective collagen is incorporated into the bone matrix, the mechanical anisotropy of the matrix is impaired, so its strength is lower and its brittleness higher than normal bone tissue.
At the cellular level, osteoblasts experience ER stress and the unfolded protein response (UPR) due to accumulation of abnormal collagen protein in the endoplasmic reticulum, causing premature osteoblast death (apoptosis) and reduced function. Reduced osteoblast numbers and function impair bone formation, while osteoclast activity is relatively maintained or increased, deepening the imbalance in which bone resorption exceeds bone formation. This leads to reduced bone mineral density (BMD), reduced cortical thickness and abnormal trabecular structure (trabecular thinning, reduced connectivity), amplifying skeletal fragility.
In recessive gene defects such as CRTAP, LEPRE1 and PPIB, deficient prolyl hydroxylation of Lys87 of the collagen α2 chain occurs, and the resulting delayed triple-helix formation and overhydroxylation cause complex structural abnormalities. In SERPINF1 (PEDF) deficiency, the normal function of PEDF in promoting osteoblast differentiation is lost, and impaired mineralization of osteoid occurs. These diverse molecular mechanisms combine to produce the common clinical phenotype of reduced bone strength, recurrent fractures, bone deformities and growth impairment.
The clinical symptoms of osteogenesis imperfecta differ widely by type, with a very broad spectrum ranging from mild recurrent fractures to perinatally lethal conditions. The common symptom is recurrent fractures from minor trauma, accompanied by various connective tissue abnormalities.
Type I (mild): the mildest phenotype, with recurrent fractures from minor trauma from childhood. Blue sclerae are characteristic, because collagen defects in the sclera make it thin, so the pigment of the underlying choroid shows through. On reaching adulthood fracture frequency decreases somewhat but increases again in pubertal and postmenopausal women. Hearing loss (conductive or mixed, due to ossicular abnormalities) develops in about 50%, usually beginning in the 20s~30s. Dentinogenesis imperfecta (DI) accompanies it in some. Joint hypermobility, flat feet and easy bruising may occur. Height is usually at the lower limit of normal or slightly short.
Type II (perinatally lethal): multiple fractures occur in utero, and at birth there are extensive bone deformities and respiratory failure. Multiple rib fractures impair lung development, and most die of respiratory complications within hours to weeks after birth. The skull is extremely soft (watermelon skull) and depresses on palpation alone, and the skin is very thin. Ultrasound reveals shortening and bowing of long bones and multiple fractures at around 16~20 weeks of gestation.
Type III (severe progressive): fractures and deformities are already present at birth, and with growth, recurrent fractures and progressive bone deformity (scoliosis, bowing of long bones) worsen. Most are unable to walk independently or are extremely limited, and adult height is very short (100 cm or less). Basilar invagination may cause brainstem compression and hydrocephalus. Blue sclerae, DI, hearing loss and reduced respiratory function are common.
Type IV (moderate): a phenotype intermediate between types I and III, with bone deformities but milder than type III. The sclerae are usually normal or slightly blue, and DI is common. Independent walking is often possible, and height is short and lower than in type I. Hearing loss also occurs.
Common symptoms: symptoms that can appear in all types include muscle weakness (muscle dysfunction due to collagen defects), joint hypermobility (collagen defects in ligaments and tendons), easy bruising (weakening of skin and vascular collagen), hernias and rectal prolapse (weakened connective tissue support) and heart valve abnormalities (aortic and mitral valve abnormalities, rare but clinically important).
The physical and imaging signs of osteogenesis imperfecta vary with type and severity. Clinicians must always differentiate these signs from child abuse (non-accidental trauma), and when suspected, genetic testing and multidisciplinary evaluation are essential.
Blue sclerae: the most characteristic sign of type I; increased transparency due to reduced scleral collagen lets the choroidal pigment show through, giving a blue to blue-gray appearance. In types III and IV it tends to fade with age. Very deep blue sclerae are seen in type II. Blue sclerae can also appear in other connective tissue diseases such as Marfan syndrome and Ehlers-Danlos syndrome.
Radiological signs: plain X-rays show generalized osteopenia, thin cortical bone, biconcave vertebral deformity (biconcave/codfish vertebrae), compression fractures, bowing of long bones and callus formation in healing fractures. Wormian bones (small bones within the sutures) on skull X-ray are characteristic. In type II, 'beaded ribs' and 'accordion femur' are typical. On dual-energy X-ray absorptiometry (DXA), the lumbar spine BMD Z-score is markedly low (below -2.0 is common), and DXA is used to follow changes in bone density with age.
Bone deformities: bowing of long bones due to recurrent fractures and incomplete healing, scoliosis, chest deformity (causing restrictive lung disease through limited chest expansion) and basilar invagination (especially in type III) appear progressively. When basilar invagination is severe, compression of the brainstem and cerebellum may be accompanied by reduced respiratory function, hydrocephalus and plagiocephaly.
Dental signs: in dentinogenesis imperfecta, primary or permanent teeth show yellow, gray or brown discoloration, accelerated wear and loss of luster, and X-rays show short roots and obliteration of the pulp chamber. DI makes dental care and prosthetics difficult, so early dental intervention is needed.
Audiological signs: conductive or mixed hearing loss due to fracture or deformity of the ossicles and otosclerosis-like findings is confirmed on hearing tests. Regular hearing tests (pure-tone audiometry, tympanometry) are recommended.
Cardiac signs: although rare, aortic root dilatation, aortic valve regurgitation and mitral valve abnormalities may be observed, so echocardiographic follow-up is needed in patients with severe phenotypes.
Universal population screening for osteogenesis imperfecta is not performed. However, when there is a family history, when abnormal findings are found on prenatal ultrasound, or when unexplained recurrent fractures occur in infants or children, systematic screening and diagnostic testing are carried out.
Prenatal ultrasound screening: pregnant women with a family history of osteogenesis imperfecta undergo detailed fetal ultrasound at 16~20 weeks of gestation (or earlier) to check for shortening, bowing and multiple fractures of long bones (femur, humerus, etc.) and undermineralization of the skull. In type II, abnormal findings may be seen from about 14~16 weeks of gestation. Ultrasound findings alone cannot always distinguish type II from type III, and confirmation by genetic testing is needed.
Prenatal genetic testing: when a COL1A1/COL1A2 variant has been identified in the family, fetal DNA is obtained by chorionic villus sampling (CVS, 11~14 weeks of gestation) or amniocentesis (15~20 weeks of gestation) and direct variant detection analysis is performed. In families with de novo mutations, analysis of the entire COL1A1/COL1A2 genes or a rare skeletal disease panel is applied. Cell-free fetal DNA analysis as noninvasive prenatal testing (NIPT) is at the research stage.
Newborn and infant screening: newborns who already have fractures or deformities at birth undergo immediate clinical evaluation and an X-ray skeletal survey. For newborns with a family history, COL1A1/COL1A2 genetic testing on blood drawn shortly after birth is recommended.
Screening of children and adults with recurrent fractures: once child abuse has been excluded, gene panel testing to differentiate causes of primary osteoporosis, including osteogenesis imperfecta, is recommended for patients with recurrent fractures, low-trauma fractures and low bone density (DXA Z-score ≤ -2.0). Clinical scoring systems (such as the OI Phenotype Score) can be used to assess the degree of clinical suspicion before genetic testing.
Bone metabolism markers: measurement of bone metabolism markers such as serum type I collagen N-terminal propeptide (P1NP), C-terminal telopeptide (CTX), alkaline phosphatase (ALP), parathyroid hormone (PTH), 25-OH vitamin D and calcium is included in the initial evaluation. These markers are not highly diagnostically specific for osteogenesis imperfecta but are used as adjuncts for treatment monitoring and for differentiating other metabolic bone diseases.
The diagnosis of osteogenesis imperfecta is made through an integrated approach of clinical findings, radiological imaging, bone density measurement, biochemical testing and molecular genetic analysis. Because clinical diagnostic criteria are not standardized, genetic testing is central to confirmation. However, even if no variant is found, a clinical diagnosis is possible if the picture is clinically consistent with osteogenesis imperfecta.
Clinical evaluation: fracture history (number, history of trauma, site, age), family history (3 or more generations), blue sclerae, dentinogenesis imperfecta, hearing loss, joint hypermobility, short stature relative to parental height and so on are assessed systematically. Determining the type according to the Sillence classification (types I~IV) or the expanded classification (type V onward) is useful for clinical management planning.
Radiological imaging: a whole-body skeletal X-ray survey assesses reduced bone density, cortical thickness, the number and healing of fractures, spinal deformity, bowing of long bones and Wormian bones. Spinal MRI checks for basilar invagination, spinal cord compression and hydrocephalus. Changes in cortical thickness after bisphosphonate treatment are monitored with long bone ultrasound or follow-up X-rays.
Bone density (DXA): BMD is measured by lumbar spine and femoral DXA, and in children Z-scores adjusted for age, sex and height are used. In osteogenesis imperfecta, Z-scores are usually markedly low (below -2.0 is common), and DXA is a key tool for assessing treatment response. Peripheral quantitative CT (pQCT) or high-resolution pQCT (HR-pQCT) is used for three-dimensional analysis of cortical and trabecular bone structure.
Biochemical tests: Serum calcium, phosphorus, ALP, PTH, 25-OH vitamin D, P1NP and CTX are measured. In osteogenesis imperfecta, ALP is usually normal but decreases after bisphosphonate treatment, and P1NP and CTX reflect bone turnover. These are used as adjuncts in differentiating vitamin D deficiency, hypophosphatasia, rickets, idiopathic juvenile osteoporosis and others.
Molecular genetic diagnosis: NGS analysis of the COL1A1/COL1A2 genes and a rare skeletal disorder panel (CRTAP, LEPRE1, PPIB, IFITM5, SERPINF1, FKBP10, SP7, etc.) is the standard. If no variant is found, whole exome sequencing (WES) or whole genome sequencing (WGS) is considered. Collagen synthesis and electrophoresis analysis of skin fibroblasts (SDS-PAGE, abnormally migrating bands) was the confirmatory method of the pre-NGS era but is now used as an adjunct. RNA analysis (evaluation of splicing variants) or functional assays are used to interpret some variants of uncertain significance (VUS).
Differentiation from child abuse: Especially in infants and young children with unexplained multiple fractures, differentiating child abuse (non-accidental trauma) from osteogenesis imperfecta is clinically very important. A multidisciplinary approach including a whole-body skeletal X-ray survey, ophthalmologic and dermatologic examination, genetic testing and social assessment is required, and definitive conclusions should be avoided before confirmation.
Treatment of osteogenesis imperfecta consists of pharmacotherapy, surgical treatment, rehabilitation, assistive devices and multidisciplinary support. A cure is currently not possible, but treatment centered on bisphosphonates contributes greatly to reducing fracture frequency and improving quality of life.
Bisphosphonate: Currently the most established pharmacotherapy; it reduces bone resorption and improves bone mineral density by inhibiting osteoclast activity. Intravenous pamidronate (pediatric: 1~3 mg/kg, at 4-month intervals) is the most widely used internationally, and clinical trials have confirmed improvement in lumbar spine Z-score, reduced fracture frequency (about 30~50%), reduced pain and improved mobility. Zoledronate (intravenous 1~2 times per year) offers greater convenience of administration and is used in adults and some children. Oral bisphosphonates (alendronate, risedronate) can be used in mild adult cases, but absorption is low and the method of administration is demanding. Major adverse effects of bisphosphonates include an acute-phase reaction at the first dose (fever, myalgia) and, rarely, osteonecrosis of the jaw (ONJ) and atypical femoral fractures, but ONJ is extremely rare in pediatric osteogenesis imperfecta.
Denosumab: An anti-RANKL monoclonal antibody that inhibits osteoclast activity. Its use is considered in patients with an insufficient response to bisphosphonates or in whom bisphosphonate use is difficult. In pediatric osteogenesis imperfecta, dose setting for denosumab and the rapid rebound in bone resorption after discontinuation are clinical challenges.
Anti-sclerostin antibody: Romosozumab neutralizes sclerostin, an inhibitor of the WNT signaling pathway, exerting a dual effect of promoting bone formation and inhibiting bone resorption. Improvement in bone mineral density has been reported in clinical trials in adult osteogenesis imperfecta (ORBIT, etc.), and studies are also under way in children.
Surgical treatment — intramedullary rodding: In patients with recurrent long-bone fractures or progressive bowing deformity, multilevel osteotomy followed by insertion of a telescoping rod (e.g., Fassier-Duval rod) is the standard operation. Telescoping rods that lengthen automatically as the child grows are used. Rodding increases the likelihood of independent ambulation and is effective in preventing fractures.
Spinal surgery: Spinal fusion is considered when progressive scoliosis reaches a Cobb angle of 40~50° or more. When basilar invagination causes neurological abnormalities, skull base decompression and spinal fusion are required.
Rehabilitation and physical therapy: Muscle strengthening, maintenance of joint range of motion, gait training and balance training are key. Hydrotherapy is effective in improving muscle strength while minimizing load on the joints. Assistive devices (brace, walker, wheelchair) are individualized according to functional level.
Hearing and dental care: For hearing loss, hearing assistive devices (hearing aids) or ossiculoplasty are considered. Dentinogenesis imperfecta requires early dental intervention, crown protection and implant planning.
Gene therapy (research stage): Mesenchymal stem cell transplantation, AAV-mediated COL1A1 gene correction, CRISPR/Cas9-based gene editing and others are at the preclinical and early clinical research stage.
The prognosis of osteogenesis imperfecta varies greatly depending on type and access to treatment. With modern multidisciplinary care and the introduction of bisphosphonates, prognosis has improved markedly compared with the past, but in patients with severe forms, serious functional impairment and shortened life expectancy remain problems.
Type I (mild): Life expectancy is nearly the same as that of the general population. Fracture frequency in childhood decreases with bisphosphonate treatment, and fractures become rare in adulthood. Hearing loss affects quality of life, and some patients need hearing aids. Independent daily living and social activity are possible. Postmenopausal decline in bone mineral density may worsen, so long-term follow-up is needed.
Type II (perinatal lethal): Most patients die of respiratory failure within hours to weeks after birth. Extremely rare cases surviving several months with intensive care have been reported, but long-term survival is very rare. Clear counseling on the non-survival prognosis and a palliative care plan are needed from birth.
Type III (progressively deforming, severe): Independent ambulation is impossible or very limited, and serious functional impairment and pain reduce quality of life. Basilar invagination and reduced respiratory function due to restrictive lung disease can be major causes of early death. Some functional improvement is possible with aggressive surgical treatment (rodding, spinal fusion), rehabilitation and bisphosphonate treatment. Life expectancy is shortened, but in the modern medical setting an increasing number of patients survive into adulthood.
Type IV (moderate): Most patients can walk independently, and life expectancy is close to normal, similar to type I. Recurrent fractures and scoliosis are ongoing problems, and function can be maintained with appropriate treatment.
Monitoring of treatment response: During bisphosphonate treatment, annual DXA, bone turnover markers (P1NP, CTX), height and weight, and fracture records are tracked. In children, whether to continue bisphosphonate treatment after completion of growth is decided individually. The treatment paradigm is changing according to clinical trial results of new-mechanism drugs (romosozumab, denosumab, TGF-β inhibitors). If gene therapy enters clinical application, the prognosis of patients with severe disease is expected to improve greatly.
Prevention of osteogenesis imperfecta itself (preventing its occurrence) is possible only through genetic counseling and preimplantation and prenatal genetic diagnosis. Clinically, however, the more important prevention is prevention of fractures and complications and suppression of progression.
Primary prevention — genetic counseling and preimplantation and prenatal diagnosis: In families of patients with osteogenesis imperfecta or carriers (both parents in AR types), when planning childbirth, risk is assessed through counseling with a genetics specialist, and unaffected embryos can be selectively implanted through preimplantation genetic testing (PGT-M), or the affected status of the fetus can be confirmed through prenatal diagnosis (CVS or amniocentesis). Considering the possibility of germline mosaicism, thorough counseling on recurrence risk is needed even when the case appears to be a de novo mutation.
Secondary prevention — early diagnosis and initiation of pharmacotherapy: In severe forms (type III, some type IV), bisphosphonate treatment is started early to lower fracture frequency and improve bone strength. Starting treatment upon the first fracture or detection of low bone mineral density (Z-score ≤ -2.0) is recommended. Adequate intake of calcium (age-specific recommended amount) and vitamin D (maintaining serum 25-OH vitamin D at 30 ng/mL or above) is ensured.
Prevention of falls and trauma: Fall-prevention measures are implemented in the home environment (non-slip mats, furniture corner guards, low beds). Individualized assistive devices are prescribed based on assessment by physical and occupational therapists. Contact sports and high-risk activities are restricted, but low-impact exercise (swimming, cycling) is recommended to maintain muscle strength and bone strength.
Tertiary prevention — suppressing progression of complications: The timing of surgical intervention is determined through regular monitoring (spine X-ray, pulmonary function tests, MRI) of progressive complications such as scoliosis, basilar invagination and decline in pulmonary function. Decline in quality of life is minimized through early intervention for hearing loss and dental problems (hearing assistive devices, protective dental treatment). Through patient and family education, they learn emergency measures for fractures, pain management and how to contact medical institutions. Support services of the Korean Organization for Rare Diseases (Korea Rare and Intractable Disease Alliance) and related patient organizations are actively used.
Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016;387(10028):1657-1671. DOI: 10.1016/S0140-6736(15)00728-X. PMID: 26542481.
Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. DOI: 10.1038/nrdp.2017.52. PMID: 28816237.
Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377-1385. DOI: 10.1016/S0140-6736(04)16051-0. PMID: 15110498.
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10:CD005088. DOI: 10.1002/14651858.CD005088.pub4. PMID: 27760454.
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-116. DOI: 10.1136/jmg.16.2.101. PMID: 458828.
Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15(9):1650-1658. DOI: 10.1359/jbmr.2000.15.9.1650. PMID: 10976985.
Monti E, Mottes M, Fraschini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367-381. DOI: 10.2147/TCRM.S5862. PMID: 20694076.
Palomo T, Vilaca T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2017;24(6):381-388. DOI: 10.1097/MED.0000000000000367. PMID: 28869438.
Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents — new developments in diagnosis and treatment. Osteoporos Int. 2016;27(12):3427-3437. DOI: 10.1007/s00198-016-3723-3. PMID: 27585604.
Schiff NB, Bhatt JM, Chang CY, et al. Clinical Practice Guidelines for Osteogenesis Imperfecta: Bone Health and Fragility. Clin Orthop Relat Res. 2021;479(8):1621-1631. DOI: 10.1097/CORR.0000000000001741. PMID: 33882022.